WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 414641
CAS#: 137275-81-1 (free base)
Description: Osemozotan Free Base is a 5-HT(1A) receptor agonist.
MedKoo Cat#: 414641
Name: Osemozotan Free Base
CAS#: 137275-81-1 (free base)
Chemical Formula: C19H21NO5
Exact Mass: 343.142
Molecular Weight: 343.38
Elemental Analysis: C, 66.46; H, 6.16; N, 4.08; O, 23.30
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 137275-81-1 (free base) 137275-80-0 (HCl)
Synonym: Osemozotan Free Base
IUPAC/Chemical Name: 3-(1,3-Benzodioxol-5-yloxy)-N-(((2S)-2,3-dihydro-1,4-benzodioxin-2-yl)methyl)propan-1-amine
InChi Key: MEEQBDCQPIZMLY-HNNXBMFYSA-N
InChi Code: InChI=1S/C19H21NO5/c1-2-5-18-16(4-1)22-12-15(25-18)11-20-8-3-9-21-14-6-7-17-19(10-14)24-13-23-17/h1-2,4-7,10,15,20H,3,8-9,11-13H2/t15-/m0/s1
SMILES Code: [C@@H]1(CNCCCOC2=CC=C(OCO3)C3=C2)OC4=CC=CC=C4OC1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 343.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Matsuda T. Neuropharmacologic studies on the brain serotonin1A receptor using the selective agonist osemozotan. Biol Pharm Bull. 2013;36(12):1871-82. doi: 10.1248/bpb.b13-00645. PMID: 24292048.
2: Tsuchida R, Kubo M, Kuroda M, Shibasaki Y, Shintani N, Abe M, Köves K, Hashimoto H, Baba A. An antihyperkinetic action by the serotonin 1A-receptor agonist osemozotan co-administered with psychostimulants or the non-stimulant atomoxetine in mice. J Pharmacol Sci. 2009 Mar;109(3):396-402. doi: 10.1254/jphs.08297fp. Epub 2009 Mar 7. PMID: 19270432.
3: Ago Y, Nakamura S, Hayashi A, Itoh S, Baba A, Matsuda T. Effects of osemozotan, ritanserin and azasetron on cocaine-induced behavioral sensitization in mice. Pharmacol Biochem Behav. 2006 Sep;85(1):198-205. doi: 10.1016/j.pbb.2006.07.036. Epub 2006 Sep 8. PMID: 16962650.
4: Ago Y, Nakamura S, Uda M, Kajii Y, Abe M, Baba A, Matsuda T. Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice. Neuropharmacology. 2006 Sep;51(4):914-22. doi: 10.1016/j.neuropharm.2006.06.001. Epub 2006 Jul 24. PMID: 16863654.
5: Tsuchida R, Kubo M, Shintani N, Abe M, Köves K, Uetsuki K, Kuroda M, Hashimoto H, Baba A. Inhibitory effects of osemozotan, a serotonin 1A-receptor agonist, on methamphetamine-induced c-Fos expression in prefrontal cortical neurons. Biol Pharm Bull. 2009 Apr;32(4):728-31. doi: 10.1248/bpb.32.728. PMID: 19336914.
6: Ago Y, Nakamura S, Baba A, Matsuda T. Neuropsychotoxicity of abused drugs: effects of serotonin receptor ligands on methamphetamine- and cocaine-induced behavioral sensitization in mice. J Pharmacol Sci. 2008 Jan;106(1):15-21. doi: 10.1254/jphs.fm0070121. Epub 2008 Jan 16. PMID: 18198473.
7: Hiramatsu N, Ago Y, Hasebe S, Nishimura A, Mori K, Takuma K, Matsuda T. Synergistic effect of 5-HT1A and σ1 receptor activation on prefrontal dopaminergic transmission under circulating steroid deficiency. Neuropharmacology. 2013 Dec;75:53-61. doi: 10.1016/j.neuropharm.2013.06.026. Epub 2013 Jul 9. PMID: 23851260.
8: Ago Y, Hasebe S, Hiramatsu N, Mori K, Watabe Y, Onaka Y, Hashimoto H, Takuma K, Matsuda T. Involvement of GABAA receptors in 5-HT1A and σ1 receptor synergism on prefrontal dopaminergic transmission under circulating neurosteroid deficiency. Psychopharmacology (Berl). 2016 Sep;233(17):3125-34. doi: 10.1007/s00213-016-4353-3. Epub 2016 Jun 23. PMID: 27339616.
9: Tanaka T, Ago Y, Umehara C, Imoto E, Hasebe S, Hashimoto H, Takuma K, Matsuda T. Role of Prefrontal Serotonergic and Dopaminergic Systems in Encounter-Induced Hyperactivity in Methamphetamine-Sensitized Mice. Int J Neuropsychopharmacol. 2017 May 1;20(5):410-421. doi: 10.1093/ijnp/pyw115. PMID: 28034961; PMCID: PMC5417057.
10: Nakamura S, Ago Y, Hayashi A, Itoh S, Kakuda M, Hashimoto H, Baba A, Matsuda T. Modification of cocaine-induced behavioral and neurochemical effects by serotonin1A receptor agonist/antagonist in mice. Synapse. 2006 Dec 1;60(7):479-84. doi: 10.1002/syn.20323. PMID: 16952156.
